An interventional study of Power resistance training in Diabetes Mellitus, Type 2 and Frailty, sponsored by Technical University of Madrid. Status unknown at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.
Sponsored by Technical University of Madrid · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 361st largest by enrollment of the 383 interventional ones that give a count, is one of 14 that started in 2020, is one of 77 with no phase, and was the 306th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Spain, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 49 · Phase 3 209 · Phase 4 51
First in 2000; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 484 across the 383 interventional studies, 842 across the 46 observational. Of the 346 that completed or were terminated, 197 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
304 of 429 have an industry lead sponsor. The 10 most frequent:
Technical University of Madrid is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Technical University of Madrid has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus, Type 2 with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07269015Hospital Mutua de TerrassaCGM Accuracy in Pregnancy Study | 2026-12 |
| NCT06871059University of the Balearic IslandsEffectiveness, Implementation and Spillover Effects of a Culturally Adapted DPP in Spanish Primary Care Centers | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes is a disease with a high impact in the population older than 65 years old. Some indications suggest that diabetes in the old age aggravate the negative effects of ageing, as the loss of muscle mass and strength, bringing the patients to a situation of vulnerability and elevated risk of disability and death known as "frailty syndrome". Recently, scientists have observed that if older population train with musculation machines emphasising the muscular power, it is possible to have an impact on a disminution of frailty and restoring the physical functionality. This project deeps in the physiological and molecular mechanisms that underlie to improvements in the frail diabetic patients.
It is hypothesised that:
The principal aims are:
Study design Longitudinal intervention stratified study, controlled and single-blinded, with a group of intervention and control group.
Based on data from a previous study recently published by the collaborators of this project. The sample size was calculated to get statistically significant differences in the physical functionality using ANCOVA and performing a bilateral contrast with alpha=0.05 of the effect of the group (with any of the independent variables), and it is needed 30 subjects by group (total n=60) to get a statistical power of 80%, with a partial eta ≥ 0.101 (value that corresponds with the size of the moderate effect).
Exercise program The intervention period will have a duration of 12 weeks, in which the training group will perform 2 sessions per week (24 sessions in total), while the control group will not perform any type of intervention, following their normal lifes and the habitual medical cares. The experimental group will perform a program focused on the muscle power training, in which there will be included exercise of upper limbs (chest press) and lower limbs (leg press). The exercises will be performed in muscle-building machines available in the reference institutions of the collaborators. It is important to point out that the intensity in the exercises will be individualised for any patient through a test of determination of muscle power validated previously by the consortium of researchers and the subjects will perform the exercises at this intensity at which the subjects will develop their maximal muscle performance, with the performance of 3-4 bouts of 8 repetitions in each exercise. After the third week of intervention, it will be put the attention to the speed of execution. The duration of each session has been estimated in 20-30 minutes.
Finally, the subjects in the control group will serve to compare the interventions with exercise and the clinical conventional treatment, as well as to determine whether the training program is able to restore the functional capacity in a similar way in diabetic patients without frailty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be enrolled in a resistance training program.
Other: Power resistance training
Participants will be doing their normal life.
Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.
Change from Baseline Glycosylated Hemoglobin (Hemoglobin A1c) at 12 weeks
Percentage
Time frame: 0 and 12 weeks.
Change from Baseline Homeostasis Model Assessment - Beta cells (HOMA2-B) at 12 weeks
Percentage
Time frame: 0 and 12 weeks.
Change from Baseline Homeostasis Model Assessment - Insuline Resistance (HOMA2-IR) at 12 weeks
Percentage
Time frame: 0 and 12 weeks.
Change from Baseline Fried frailty score at 6 and 12 weeks
Level of frailty assessed by Fried Criteria. Intermediate or prefrail: 1 or 2 criteria present. Positive for frailty phenotype: ≥3 criteria present.
Time frame: 0, 6 and 12 weeks.
Change from Baseline Functional capacity at 6 and 12 weeks
Level of functional capacity assessed by the test SPPB. Scores 0-3: Very low physical function; Scores 4-6: Low physical function; Scores 7-9: Moderate physical function; Scores 10-12: High physical function
Time frame: 0, 6 and 12 weeks.
Change from Baseline Disability at 6 and 12 weeks
Level of disability assessed by the Barthel test. A participant scoring 0 points would be dependent in all assessed activities of daily living, whereas a score of 100 would reflect independence in these activities.
Time frame: 0, 6 and 12 weeks.
Functional mobility at 6 and 12 weeks
Level of functional mobility assessed by the Lawton test. A scale from 0 to 8, expressing higher scores better levels of independence.
Time frame: 0, 6 and 12 weeks.
Change from Baseline Muscular power at 6 and 12 weeks
Watts.
Time frame: 0, 6 and 12 weeks.
Change from Baseline Levels of strength at 6 and 12 weeks
Load (kg).
Time frame: 0, 6 and 12 weeks.
Change from Baseline Bone Mineral Density at 12 weeks
g/cm3
Time frame: 0 and 12 weeks.
Change from Baseline Pigment Epitelium Derived Factor (PEDF) at 12 weeks
Circulating level of PDEF assessed by Western Blot.
Time frame: 0 and 12 weeks.
Genotyping of TCF7L2 (rs7903146)
Assessed by Real-time PCR.
Time frame: 0 week.
Genotyping of TM6SF2 (rs10401969)
Assessed by Real-time PCR.
Time frame: 0 week.
Genotyping of HLA (rs2854275)
Assessed by Real-time PCR.
Time frame: 0 week.
Change from Baseline Body Mass Index at 6 and 12 weeks
Kg by square meters.
Time frame: 0, 6 and 12 weeks.
Change from Baseline Waist circumference at 6 and 12 weeks
Meters.
Time frame: 0, 6 and 12 weeks.
Change from Baseline Blood pressure (systolic and diastolic) at 6 and 12 weeks
mmHg.
Time frame: 0, 6 and 12 weeks.
Change from Baseline Concentration of Triglycerides at 12 weeks
mg/dL.
Time frame: 0 and 12 weeks.
Change from Baseline Concentration of Total Cholesterol at 12 weeks
mg/dL.
Time frame: 0 and 12 weeks.
Change from Baseline Concentration of HDL Cholesterol at 12 weeks
mg/dL.
Time frame: 0 and 12 weeks.
Change from Baseline Concentration of LDL Cholesterol at 12 weeks
mg/dL.
Time frame: 0 and 12 weeks.
Change from Baseline Subjective level of quality of life at 12 weeks
Level of quality of life assessed by the test EuroQoL index, EQ-5D-5L. The score is the time trade-off (TTO). Scale from 11111 to 55555 being the higher the best health related quality of life.
Time frame: 0 and 12 weeks.
Change from Baseline Physical activity at 12 weeks
Accelerometry, counts/min.
Time frame: 0 and 12 weeks.
Change from Baseline Balance at 12 weeks
Level of balance assessed in a force platform. Newtons.
Time frame: 0 and 12 weeks.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individualised report to all the participants after the completion of the study.
Supporting information: Analytic code
Time frame: At the end of the intervention.
Access criteria: The participants who have accepted to have the report.
Ran from Jan 2020 to primary completion in May 2020, 4 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 4 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Madrid